All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis

Mammalian target of rapamycin (mTOR) is a crucial molecule in the control of cell size and proliferation; dysregulation of the mTOR pathway is commonly found in human cancers. Many cancer-promoting kinases have been identified as regulators of mTOR activity through phosphorylation and inactivation of the TSC1–TSC2 complex. Tumor-associated macrophages (TAMs) are tumor-promoting factors in inflammation-mediated tumor development, and the signaling molecules involved in TAMs-mediated tumor angiogenesis are not well understood. Therefore, it is urgent to elucidate the cross-talk between inflammatory cells and cancers and to explore the precise pathways involved in TAMs-induced tumor angiogenesis. Recently IKKβ was found to activate the mTOR pathway and to promote tumor angiogenesis through inactivation of the TSC1–TSC2 complex by phosphorylating TSC1. This finding provides critical insights into and suggests one mechanism behind inflammation-mediated tumor angiogenesis. In this extra-view, we briefly discuss the possible influence of TAMs-released proangiogenic factors on mTOR activation and propose a model of the cross-talk between tumors and TAMs in tumor angiogenesis.

[1]  G. Hortobagyi,et al.  IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway , 2007, Cell.

[2]  A. Griffioen,et al.  Monocyte/macrophage infiltration in tumors: modulators of angiogenesis , 2006, Journal of leukocyte biology.

[3]  Ming You,et al.  TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.

[4]  Chun-chung Lee,et al.  Tumor necrosis factor-alpha, Interleukin-8 and Interleukin-6 are involved in vascular endothelial cell capillary tube and network formation induced by tumor-associated macrophages , 2006 .

[5]  Shao-Cong Sun,et al.  Regulation of the Deubiquitinating Enzyme CYLD by IκB Kinase Gamma-Dependent Phosphorylation , 2005, Molecular and Cellular Biology.

[6]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[7]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[8]  E. Hafen,et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. , 2004, Genes & development.

[9]  Steven P Gygi,et al.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[11]  Ryuji Kobayashi,et al.  IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. , 2004, Cell.

[12]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.

[13]  E. Henske,et al.  Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B* , 2003, Journal of Biological Chemistry.

[14]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[15]  Hongbing Zhang,et al.  Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. , 2003, Cancer research.

[16]  K. Inoki,et al.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.

[17]  E. Hafen,et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.

[18]  K. Inoki,et al.  The p38 and MK2 Kinase Cascade Phosphorylates Tuberin, the Tuberous Sclerosis 2 Gene Product, and Enhances Its Interaction with 14-3-3* , 2003, The Journal of Biological Chemistry.

[19]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Kwiatkowski,et al.  Tuberous Sclerosis: from Tubers to mTOR , 2003, Annals of human genetics.

[21]  S. Nicosia,et al.  Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of Tuberin* , 2002, The Journal of Biological Chemistry.

[22]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[23]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[24]  A. Manning,et al.  Fanconi anemia protein complex is a novel target of the IKK signalsome , 2002, Journal of cellular biochemistry.

[25]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[26]  D. Kwiatkowski,et al.  Molecular genetic advances in tuberous sclerosis , 2000, Human Genetics.

[27]  T. Tamaya,et al.  Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. , 2000, Cancer research.

[28]  S Povey,et al.  The genetic basis of tuberous sclerosis. , 1998, Molecular medicine today.

[29]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[30]  R. Derynck,et al.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.